Journal
ALZHEIMERS & DEMENTIA
Volume 17, Issue 10, Pages 1756-1762Publisher
WILEY
DOI: 10.1002/alz.12324
Keywords
Alzheimer' s disease; early detection; mild cognitive impairment; neurofilament light; subtle cognitive decline
Categories
Funding
- U.S. Department of Veterans Affairs Clinical Sciences Research and Development Service (Merit Award) [1I01CX001842]
- U.S. Department of Veterans Affairs Clinical Sciences Research and Development Service ( Career Development Award-2) [1IK2CX001865, 1IK2CX001415]
- National Institute on Aging/National Institutes of Health (NIA/NIH) [R01 AG063782, R01 AG049810, R01 AG054049, R03 AG070435, P30 AG062429]
- Alzheimer's Association [AARF-17-528918, AARG-18-566254, AARG-17-500358]
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH) [U01 AG024904]
- DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
- NIA, the National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- Alzheimer's Association
- Alzheimer's DrugDiscovery Foundation
- Araclon Biotech
- BioClinica, Inc.
- Biogen
- Bristol-Myers Squibb Company
- CereSpir, Inc.
- Cogstate
- Eisai Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- EuroImmun
- F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
- Fujirebio
- GE Healthcare
- IXICO Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC.
- Johnson & Johnson Pharmaceutical Research & Development LLC.
- Lumosity
- Lundbeck
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC.
- NeuroRx Research
- Neurotrack Technologies
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Piramal Imaging
- Servier
- Takeda Pharmaceutical Company
- Transition Therapeutics
- Canadian Institutes of Health Research
Ask authors/readers for more resources
The study demonstrates the utility of plasma NFL as a biomarker of early AD-related changes, and supports the use of Obj-SCD criteria in clinical research to better capture subtle cognitive changes. Individuals with Obj-SCD and MCI showed elevated baseline plasma NFL relative to the cognitively normal group, and elevated NFL predicted faster rate of cognitive and functional decline across the sample. Within the Obj-SCD and MCI groups, higher NFL levels predicted faster rate of decline in memory and preclinical AD composite score compared to the cognitively normal group.
Introduction Neurofilament light (NFL) reflects neuroaxonal damage and is implicated in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Little is known about NFL in pre-MCI stages, such as in individuals with objectively-defined subtle cognitive decline (Obj-SCD). Methods Two hundred ninety-four participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent baseline blood draw and serial neuropsychological testing over 5 years of follow-up. Results Individuals with Obj-SCD and MCI showed elevated baseline plasma NFL relative to the cognitively normal (CN) group. Across the sample, elevated NFL predicted faster rate of cognitive and functional decline. Within the Obj-SCD and MCI groups, higher NFL levels predicted faster rate of decline in memory and preclinical AD composite score compared to the CN group. Discussion Findings demonstrate the utility of plasma NFL as a biomarker of early AD-related changes, and provide support for the use of Obj-SCD criteria in clinical research to better capture subtle cognitive changes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available